STOCK TITAN

Beta Bionics CEO sells 16,867 shares for taxes

Beta Bionics’ President & CEO sold shares to cover tax withholding from RSU vesting, retaining over 400,000 shares afterward.

(High)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) reported that President & CEO Sean Saint sold 16,867 shares of common stock on September 2, 2026 at a weighted average price of $19.1131 per share. According to the disclosure, the shares were sold to cover tax withholding obligations from vesting restricted stock units, and Saint held 404,070 shares directly after the transaction.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Saint Sean
Role President & CEO
Sold 16,867 shs ($322K)
Type Security Shares Price Value
Sale Common Stock F1, F2 16,867 $19.1131 $322K
Holdings After Transaction: Common Stock — 404,070 shares (Direct)
Footnotes (2)
  1. F1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
  2. F2. The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Shares sold 16,867 shares Common stock sale by President & CEO on September 2, 2026
Weighted average sale price $19.1131 per share Sale of 16,867 shares on September 2, 2026
Post-transaction holdings 404,070 shares Shares directly owned by Sean Saint after the sale
Sale price range low $18.89 per share Lowest price in the reported sale range
Sale price range high $19.545 per share Highest price in the reported sale range
restricted stock units financial
"associated with the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"sold to cover tax withholding obligations associated"
weighted average sale price financial
"The weighted average sale price for the transaction"

FAQ

What insider transaction did BBNX report for President & CEO Sean Saint?

Sean Saint reported a sale of 16,867 shares of Beta Bionics common stock on September 2, 2026, at a weighted average price of $19.1131 per share, primarily to cover tax withholding obligations from vesting restricted stock units.

How many BBNX shares does Sean Saint hold after this Form 4 transaction?

After the reported sale, Sean Saint directly held 404,070 shares of Beta Bionics common stock. This figure is disclosed as the total number of shares beneficially owned following the September 2, 2026 transaction.

Why did the BBNX CEO sell 16,867 shares according to the Form 4?

The filing states that the 16,867 shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units, indicating the transaction was related to equity compensation rather than a discretionary open-market sale.

What price range did the BBNX insider sales occur at on September 2, 2026?

The filing reports a weighted average sale price of $19.1131 per share, with individual trades executed in a price range between $18.89 and $19.545 for the 16,867 shares sold.

Was the BBNX CEO’s September 2, 2026 sale under a Rule 10b5-1 trading plan?

No. The document-level checkbox indicates no Rule 10b5-1 plan for this Form 4, and the footnotes describe the sale as being to cover tax withholding obligations from restricted stock unit vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Saint Sean

(Last)(First)(Middle)
C/O BETA BIONICS, INC.
11 HUGHES

(Street)
IRVINE CALIFORNIA 92618

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/02/2026S(1)16,867D$19.1131(2)404,070D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
2. The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Stephen Feider, Attorney-in-Fact09/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading